These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 30649747

  • 1. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
    Wolska-Washer A, Robak T.
    Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
    [Abstract] [Full Text] [Related]

  • 2. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
    Jackson D, Stover D.
    Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
    [Abstract] [Full Text] [Related]

  • 3. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.
    Goldmacher VS, Kovtun YV.
    Ther Deliv; 2011 Mar; 2(3):397-416. PubMed ID: 22834009
    [Abstract] [Full Text] [Related]

  • 4. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
    Kamath AV, Iyer S.
    Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
    [Abstract] [Full Text] [Related]

  • 5. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J.
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [Abstract] [Full Text] [Related]

  • 6. Picking the optimal target for antibody-drug conjugates.
    Mathur R, Weiner GJ.
    Am Soc Clin Oncol Educ Book; 2013 Sep. PubMed ID: 23714470
    [Abstract] [Full Text] [Related]

  • 7. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH.
    Life Sci; 2024 Jun 15; 347():122676. PubMed ID: 38688384
    [Abstract] [Full Text] [Related]

  • 8. Antibody-drug Conjugate Targets, Drugs, and Linkers.
    Teicher BA, Morris J.
    Curr Cancer Drug Targets; 2022 Jun 15; 22(6):463-529. PubMed ID: 35209819
    [Abstract] [Full Text] [Related]

  • 9. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
    Okeley NM, Alley SC, Senter PD.
    Hematol Oncol Clin North Am; 2014 Feb 15; 28(1):13-25. PubMed ID: 24287064
    [Abstract] [Full Text] [Related]

  • 10. Antibody-drug conjugate targets.
    Teicher BA.
    Curr Cancer Drug Targets; 2009 Dec 15; 9(8):982-1004. PubMed ID: 20025606
    [Abstract] [Full Text] [Related]

  • 11. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE, Cotreau M, Han TH, Gupta M.
    J Clin Pharmacol; 2017 Oct 15; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [Abstract] [Full Text] [Related]

  • 12. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W, Zhang J, Xiang J, Zhang L, Wu C, Dhal PK, Chen B.
    Curr Cancer Drug Targets; 2016 Oct 15; 16(6):469-79. PubMed ID: 27174056
    [Abstract] [Full Text] [Related]

  • 13. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
    Robak T, Robak E.
    Expert Opin Investig Drugs; 2014 Jul 15; 23(7):911-24. PubMed ID: 24708159
    [Abstract] [Full Text] [Related]

  • 14. [Design of next generation antibody drug conjugates].
    Zhu GD, Fu YX.
    Yao Xue Xue Bao; 2013 Jul 15; 48(7):1053-70. PubMed ID: 24133971
    [Abstract] [Full Text] [Related]

  • 15. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?
    Esteva FJ, Miller KD, Teicher BA.
    Am Soc Clin Oncol Educ Book; 2015 Jul 15; ():e117-25. PubMed ID: 25993162
    [Abstract] [Full Text] [Related]

  • 16. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.
    Ann N Y Acad Sci; 2014 Aug 15; 1321():41-54. PubMed ID: 25123209
    [Abstract] [Full Text] [Related]

  • 17. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J, Jiang F, Lu A, Zhang G.
    Int J Mol Sci; 2016 Apr 14; 17(4):561. PubMed ID: 27089329
    [Abstract] [Full Text] [Related]

  • 18. Emerging antibody-drug conjugates for treating lymphoid malignancies.
    Wolska-Washer A, Robak P, Smolewski P, Robak T.
    Expert Opin Emerg Drugs; 2017 Sep 14; 22(3):259-273. PubMed ID: 28792782
    [Abstract] [Full Text] [Related]

  • 19. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U, Parakh S, Gan HK, Scott AM.
    Molecules; 2020 Oct 16; 25(20):. PubMed ID: 33081383
    [Abstract] [Full Text] [Related]

  • 20. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A, Goetsch L, Dumontet C, Corvaïa N.
    Nat Rev Drug Discov; 2017 May 16; 16(5):315-337. PubMed ID: 28303026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.